Switch theme
Sign up to access all valuation multiples
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
2017
191
Last FY Revenue n/a
LTM EBITDA -$391M
$676M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dyne Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$391M.
In the most recent fiscal year, Dyne Therapeutics achieved revenue of n/a and an EBITDA of -$342M.
Dyne Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dyne Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$391M | XXX | -$342M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$411M | XXX | -$344M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$393M | XXX | -$317M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Dyne Therapeutics's stock price is $9.
Dyne Therapeutics has current market cap of $1.3B, and EV of $676M.
See Dyne Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $676M | $1.3B | XXX | XXX | XXX | XXX | $-3.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Dyne Therapeutics has market cap of $1.3B and EV of $676M.
Dyne Therapeutics's trades at n/a EV/Revenue multiple, and -2.0x EV/EBITDA.
Equity research analysts estimate Dyne Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dyne Therapeutics has a P/E ratio of -3.4x.
See valuation multiples for Dyne Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $676M | XXX | $676M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | -2.0x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.4x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | -4.4x | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDyne Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Dyne Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dyne Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dyne Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dyne Therapeutics acquired XXX companies to date.
Last acquisition by Dyne Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Dyne Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dyne Therapeutics founded? | Dyne Therapeutics was founded in 2017. |
| Where is Dyne Therapeutics headquartered? | Dyne Therapeutics is headquartered in United States of America. |
| How many employees does Dyne Therapeutics have? | As of today, Dyne Therapeutics has 191 employees. |
| Who is the CEO of Dyne Therapeutics? | Dyne Therapeutics's CEO is Mr. John G. Cox. |
| Is Dyne Therapeutics publicy listed? | Yes, Dyne Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Dyne Therapeutics? | Dyne Therapeutics trades under DYN ticker. |
| When did Dyne Therapeutics go public? | Dyne Therapeutics went public in 2020. |
| Who are competitors of Dyne Therapeutics? | Similar companies to Dyne Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Dyne Therapeutics? | Dyne Therapeutics's current market cap is $1.3B |
| Is Dyne Therapeutics profitable? | Yes, Dyne Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dyne Therapeutics? | Dyne Therapeutics's last 12 months EBITDA is -$391M. |
| What is the current EV/EBITDA multiple of Dyne Therapeutics? | Current EBITDA multiple of Dyne Therapeutics is -1.7x. |
| What is the current FCF of Dyne Therapeutics? | Dyne Therapeutics's last 12 months FCF is -$153M. |
| What is the current EV/FCF multiple of Dyne Therapeutics? | Current FCF multiple of Dyne Therapeutics is -4.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
